The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.

Abstract

BACKGROUND Several epidemiological studies have shown that postprandial hyperglycemia is associated with an increased risk of cardiovascular disease (CVD). The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2 diabetes. METHODS A total of 37 patients with… (More)
DOI: 10.1016/j.cca.2008.01.005

Topics

5 Figures and Tables

Cite this paper

@article{Hasegawa2008TheAI, title={The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.}, author={Goji Hasegawa and Shizuo Kajiyama and Toru Tanaka and Saeko Imai and Hana Kozai and Aya Fujinami and Mitsuhiro Ohta and Hiroshi Obayashi and Hyohun Park and Koji Nakano and Muhei Tanaka and Emi Shiraishi and Michiaki Fukui and Toshikazu Yoshikawa and Naoto Nakamura}, journal={Clinica chimica acta; international journal of clinical chemistry}, year={2008}, volume={390 1-2}, pages={110-4} }